Gamma Knife Radiosurgery

Property	Information
Drug Name	Gamma Knife Radiosurgery (GKRS) for GBM
FDA Approval	Yes
Used for	Newly diagnosed Glioblastoma Multiforme (GBM)
Clinical Trial Phase	N/A (Established treatment modality)
Clinical Trial Explanation	Not specified
Common Side Effects	Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.
OS without	14-16 months with standard treatment.
OS with	Comparable to standard treatment, specifics depend on individual patient factors.
PFS without	Typically, tumors recur within 6 months of standard treatment.
PFS with	5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.
Usefulness Rating	3
Usefulness Explanation	The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.
Toxicity Level	2
Toxicity Explanation	GKRS, especially when utilized in a fractionated approach with the Gamma Knife ICON, presents a viable treatment option for GBM patients, emphasizing reduced side effects while maintaining efficacy.

Links: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10162-w

From Ben Williams Book: Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.Property "Has original text" (as page type) with input value "Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...